Werewolf Therapeutics
HOWL
37 hedge funds and large institutions have $62.5M invested in Werewolf Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 8 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
46% more capital invested
Capital invested by funds: $42.8M → $62.5M (+$19.7M)
0.11% more ownership
Funds ownership: 67.89% → 68% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 38 → 37 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.52M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.75M |
| 3 |
Millennium Management
New York
|
+$772K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$571K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$360K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$505K |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
-$264K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$208K |
| 4 |
Renaissance Technologies
New York
|
-$132K |
| 5 |
E
Ergoteles
New York
|
-$54.3K |
HOWL Hedge Fund Activity: Q1 2023 in Review
37 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q1 2023, worth a combined $62.5M — up 46% from $42.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HOWL and 7 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 12 added.
The largest buyer was RA Capital Management, adding an estimated $5.52M. The largest seller was Oasis Management Company, exiting entirely with an estimated $505K sold.
- 37 institutional investors held Werewolf Therapeutics (HOWL) as of Q1 2023, down from 38 in Q4 2022.
- Funds reported $62.5M of Werewolf Therapeutics stock for Q1 2023, up 46% quarter-over-quarter.
- 7 funds opened new Werewolf Therapeutics positions in Q1 2023 and 8 closed out, a net change of -1 holder.
- The largest Werewolf Therapeutics buyer in Q1 2023 was RA Capital Management, an estimated $5.52M added.
- The largest Werewolf Therapeutics seller in Q1 2023 was Oasis Management Company, an estimated $505K sold.
Based on aggregated 13F filings for Q1 2023.